Posts

Showing posts with the label metastatic lung cancer

EPS for EuroDry Ltd. (EDRY) Expected At $0.22; Bollard Group Has Boosted Merck & Co (MRK) Holding By $468,930 - The FinHeadLines

Image
Analysts expect EuroDry Ltd. (NASDAQ:EDRY) to report $0.22 EPS on February, 21.EDRY’s profit would be $495,899 giving it 9.18 P/E if the $0.22 EPS is correct. After having $0.62 EPS previously, EuroDry Ltd.’s analysts see -64.52% EPS growth. The stock decreased 2.42% or $0.2 during the last trading session, reaching $8.08. About 2,543 shares traded. EuroDry Ltd. (NASDAQ:EDRY) has 0.00% since January 27, 2018 and is . It has by 0.00% the S&P500. Bollard Group Llc increased Merck & Co Inc (MRK) stake by 6.64% reported in 2018Q3 SEC filing. Bollard Group Llc acquired 6,699 shares as Merck & Co Inc (MRK)’s stock rose 11.30%. The Bollard Group Llc holds 107,528 shares with $7.63 million value, up from 100,829 last quarter. Merck & Co Inc now has $189.70B valuation. The stock decreased 0.30% or $0.22 during the last trading session, reaching $72.95. About 13.41M shares traded. Merck & Co., Inc. (NYSE:MRK) has risen 41.35% since January 27, 2018 and is uptrending. It has...

First-line immunotherapy does not improve survival in metastatic lung cancer - The Pharmaceutical Journal

Image
Neither single nor combination first-line immunotherapy significantly extends survival, compared with chemotherapy, in metastatic non small-cell lung carcinoma (NSCLC), trial results published in Annals of Oncology (December 2018) have shown [1] . In the phase III trial, 1,118 treatment-naive patients were randomly assigned to durvalumab, durvalumab plus tremelimumab, or chemotherapy. Of these, 488 patients had tumour cell expression of the receptor PD-L1 of 25% or greater, indicating that they were more likely to respond to immunotherapy.  Among these patients, median overall survival was greater with first-line durvalumab alone at 16.3 months versus 12.9 months for chemotherapy alone; however, it should be noted that while the authors described this as “clinically meaningful”, it did not reach statistical significance. There was no significant difference in overall survival between durvalumab plus tremelimumab and chemotherapy, nor in progression-free survival between any o...

One more fight: Green Beret says military failed to detect his cancer. Now he seeks to hold the government accountable - Stars and Stripes

Image
WASHINGTON — If there’s one skill that’s kept Sgt. 1st Class Rich Stayskal going for more than a decade in Special Forces it’s his ability to keep his eyes on the end game. It helped the former Marine recover from a gunshot wound to his lung while fighting in Iraq and go on to become a Green Beret two years later. And it helps explain how this 37-year-old father of two with terminal stage IV metastatic lung cancer that has spread to his spine, neck, pelvis, lymph nodes, liver, spleen and hip is willing to forgo much-needed rest and precious time with his daughters to lobby Congress for change. Had his military doctors diagnosed him properly, Stayskal believes he would be cancer-free today. Instead, he says, they failed to flag his cancer when it appeared visibly on a scan in January 2017, and again failed to inform him about it four months later when he was passing out and coughing up blood. He was so sick that his commanding officer at Fort Bragg walked across base with him to Woma...

A Green Beret says the military failed to detect his cancer. Now he seeks to hold the government accountable. - Stars and Stripes

Image
WASHINGTON — If there’s one skill that’s kept Sgt. 1st Class Rich Stayskal going for more than a decade in Special Forces it’s his ability to keep his eyes on the end game. It helped the former Marine recover from a gunshot wound to his lung while fighting in Iraq and go on to become a Green Beret two years later. And it helps explain how this 37-year-old father of two with terminal stage IV metastatic lung cancer that has spread to his spine, neck, pelvis, lymph nodes, liver, spleen and hip is willing to forgo much-needed rest and precious time with his daughters to lobby Congress for change. Had his military doctors diagnosed him properly, Stayskal believes he would be cancer-free today. Instead, he says, they failed to flag his cancer when it appeared visibly on a scan in January 2017, and again failed to inform him about it four months later when he was passing out and coughing up blood. He was so sick that his commanding officer at Fort Bragg walked across base with him to Woma...

As Mondelez Intl (MDLZ) Share Price Rose, First Manhattan Company Boosted Stake; Tealwood Asset Management Has Increased Its Merck & Co (MRK) Holding by $506,800 as Stock Price Rose - The Moveefy

Image
Tealwood Asset Management Inc increased its stake in Merck & Co Inc (MRK) by 8.82% based on its latest 2018Q3 regulatory filing with the SEC. Tealwood Asset Management Inc bought 7,240 shares as the company’s stock rose 11.30% while stock markets declined. The institutional investor held 89,283 shares of the health care company at the end of 2018Q3, valued at $6.33M, up from 82,043 at the end of the previous reported quarter. Tealwood Asset Management Inc who had been investing in Merck & Co Inc for a number of months, seems to be bullish on the $194.77 billion market cap company. The stock increased 0.56% or $0.42 during the last trading session, reaching $74.9. About 9.43 million shares traded. Merck & Co., Inc. (NYSE:MRK) has risen 41.35% since January 13, 2018 and is uptrending. It has outperformed by 41.35% the S&P500. Some Historical MRK News: 16/04/2018 – BRISTOL-MYERS SQUIBB – IN PHASE 3 CHECKMATE -214 TRIAL, OPDIVO + YERVOY ALSO DELIVERED DURABLE RESPONSES, WI...

How a new treatment could cure stage 4 lung cancer - KPRC Click2Houston

Image
HOUSTON - The end of August 2017 was depressing for everyone in Houston, but for Nanci Rose, it was especially heartbreaking. “Really had no will to live,” she said. She was married for 35 years when her husband died of cancer and, she says, their home went under water in the same week. Then it got worse. She was diagnosed with metastatic lung cancer. Her doctors told her it had spread and the outcome would not be good. “I was taking care of him. That was a 24/7 job. So, I guess I really wasn't tuned into what was going on with me,” Rose admitted. Even without much will to live, she said she couldn't suffer through the symptoms and went to Dr. Eric Bernicker at Houston Methodist. He put her on an immunotherapy drug in clinical trial and that changed everything. “Our approach has been in people who have not been treated with any type of therapy. Either chemo or immunotherapy to try and utilize this approach up front,” Dr. Eric Bernicker, Houston Methodist thoracic oncolog...

Merck & Co. (MRK) Holder Strategic Financial Services Lowered Holding by $560,700 as Shares Rose; Johnson & Johnson (JNJ) Share Value Rose While DL Carlson Investment Group Boosted by $840,834 Its Stake - The Moveefy

Image
Strategic Financial Services Inc decreased its stake in Merck & Co. (MRK) by 7.82% based on its latest 2018Q3 regulatory filing with the SEC. Strategic Financial Services Inc sold 8,010 shares as the company’s stock rose 11.30% while stock markets declined. The institutional investor held 94,475 shares of the health care company at the end of 2018Q3, valued at $6.70 million, down from 102,485 at the end of the previous reported quarter. Strategic Financial Services Inc who had been investing in Merck & Co. for a number of months, seems to be less bullish one the $197.31B market cap company. The stock increased 0.59% or $0.45 during the last trading session, reaching $75.88. About 6.65M shares traded. Merck & Co., Inc. (NYSE:MRK) has risen 41.35% since January 8, 2018 and is uptrending. It has outperformed by 41.35% the S&P500. Some Historical MRK News: 06/04/2018 – NEWLINK GENETICS – IN LIGHT OF INCYTE’S ANNOUNCEMENT REGARDING ECHO-301 TRIAL, CO UNDERTAKING REVIEW OF C...

Wife of late firefighter still battling for recognition - Gloucester Daily Times

Image
MaryBeth Smith says one of the hardest things to think about regarding her husband's death is that if he ventured into a blaze like the 1998 Fisherman's Wharf fire now, he would be protected. "They didn't have the proper apparatus, they didn't have enough (units)," she recalls, having lived the last six years as a single mom raising three boys. "He was breathing in everything that was there — the chemicals, the materials treating the nets, everything. If it were today, none of this would be happening." But she also has no doubt in her mind that her late husband, Gloucester firefighter Michael Smith — who contracted non-Hodgkins lymphoma and passed away six years ago due to metastatic lung cancer — died in the line of service. She has sought medical opinions from specialists at Mass General, Mount Sinai and elsewhere who all agree that Smith's cancer was directly linked to him breathing through that infamous fire. "There is no question h...

Clinical course of EGFR-mutant NSCLC transforming to SCLC documented - medwireNews

Image
medwireNews : Epidermal growth factor receptor ( EGFR )-mutant non-small-cell lung cancer (NSCLC) that transforms to small-cell lung cancer (SCLC) is characterized by a high rate of TP53 mutation and a lack of response to immunotherapy, among other features, show researchers. Lecia Sequist (Massachusetts General Hospital, Boston, USA) and colleagues say that “little is known about the clinical course of patients with EGFR -mutant cancer after SCLC transformation, which leads to uncertainty about appropriate treatments and prognostic implications for clinicians.” Advertisement To address this, they performed a retrospective chart review of 67 patients (median age 56 years, 57% women) with EGFR -mutant SCLC or high-grade neuroendocrine carcinoma. At the time of initial lung cancer diagnosis, 87% of the patients had NSCLC histology, predominantly adenocarcinoma, and 13% had de novo SCLC or mixed histology including SCLC. All of the patients carried EGFR mutations, most commonl...

USU mourns death of police officer from lung cancer - The Herald Journal

Image
Prayers for a full recovery quickly turned to sorrow this week with the passing of Utah State University police officer Andy Barnes on Dec. 12, barely a week after he was diagnosed with metastatic lung cancer. “Andy was an important part of the Utah State University Public Safety team and was well respected across campus and in the community,” USU Chief of Police Michael Kuehn said. “Andy was an amazing example of selfless love, always thinking of others and had a kind word or joke ready for his co-workers. He will be truly missed by all of us.” Barnes, 45, is a Cache Valley native and leaves behind his wife, Cathrine, and their three children. Advertisement Kuehn said Barnes’s quick wit, calm disposition and commitment to professionalism while working with others enabled him to easily earn the trust and respect of the USU and Cache Valley communities. As a young adult, Barnes volunteered with the Cache County Sheriff’s Office Search and Rescue team, and in 1998, he st...

A New Age of Hope in Lung Cancer Treatment - WPLG Local 10

Image
Dr. Gilberto Lopes is a medical oncologist at Sylvester Comprehensive Cancer Center, part of UHealth, University of Miami Health System. If you have further questions about lung cancer treatment at Sylvester, or to schedule an appointment, call 305-243-1000 . Traci Sherman was referred to an ophthalmologist when she started seeing black dots earlier this year, mistakenly thinking it was a torn retina or some other problem with the anatomy of her eye. She soon learned the spots were the result of cancerous lesions on her brain. Those lesions, as well as additional tumors in her lymph and pelvic bone, were caused by cancer originating in her lungs. “It was a shock,” says Traci, who at the age of 52, felt healthy and strong and had no symptoms outside of the slight impairment of her vision. In the weeks following her diagnosis of Stage 4 metastatic lung cancer, Traci initiated treatment under the care of Dr. Gilberto Lopes, a medical oncologist at Sylvester Comprehensive Cancer Center...

DSO head Anne Parsons undergoing treatment for lung cancer - The Detroit News

Roche wins key cancer drug approval, but taking on Merck remains a challenge - BioPharma Dive

A New Age of Hope in Lung Cancer Treatment - WPLG Local 10

Image
Dr. Gilberto Lopes is a medical oncologist at Sylvester Comprehensive Cancer Center, part of UHealth, University of Miami Health System. If you have further questions about lung cancer treatment at Sylvester, or to schedule an appointment, call 305-243-1000 . Traci Sherman was referred to an ophthalmologist when she started seeing black dots earlier this year, mistakenly thinking it was a torn retina or some other problem with the anatomy of her eye. She soon learned the spots were the result of cancerous lesions on her brain. Those lesions, as well as additional tumors in her lymph and pelvic bone, were caused by cancer originating in her lungs. “It was a shock,” says Traci, who at the age of 52, felt healthy and strong and had no symptoms outside of the slight impairment of her vision. In the weeks following her diagnosis of Stage 4 metastatic lung cancer, Traci initiated treatment under the care of Dr. Gilberto Lopes, a medical oncologist at Sylvester Comprehensive Cancer Center...

FDA Approves Genentech's Tecentriq in Combination With Avastin and Chemotherapy for the Initial Treatment of People With a Specific Type of Metastatic Lung Cancer - Business Wire

Image
SOUTH SAN FRANCISCO, Calif.--( BUSINESS WIRE )--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) approved Tecentriq ® (atezolizumab), in combination with Avastin ® (bevacizumab), paclitaxel and carboplatin (chemotherapy), for the initial (first-line) treatment of people with metastatic non-squamous non-small cell lung cancer (NSCLC) with no EGFR or ALK genomic tumor aberrations. “This Tecentriq regimen has demonstrated a significant survival benefit in the initial treatment of metastatic non-squamous non-small cell lung cancer,” said Sandra Horning, M.D., chief medical officer and head of Global Product Development. “Today’s approval supports our combination approach for Tecentriq in lung cancer and our vision to develop medicines that improve outcomes for patients with this complex disease.” This approval is based on results from the Phase III IMpower150 study, which showed that Tecentriq in comb...